Do Kien Hung, Do Tu Anh, Nguyen Tai Van, Le Duc Thanh, Phan Linh Van, Nguyen Chu Van
National Cancer Hospital, Hanoi, Vietnam.
Hanoi Medical University, Hanoi, Vietnam.
Int J Hematol Oncol Stem Cell Res. 2024 Jul 1;18(3):262-273. doi: 10.18502/ijhoscr.v18i3.16107.
Extranodal natural killer (NK)/T-cell lymphoma, nasal type is a rare, aggressive, and poor prognostic subtype. The concurrent chemoradiotherapy followed by chemotherapy showed a relatively high response rate and the toxicity due to the treatment is acceptable. The study attempted to report the clinicopathological features, the survival outcome, and response rates of stages I-II, nasal type ENKTL patients treated with CCRT followed by adjuvant VIPD chemotherapy in Vietnam. The current study was conducted on 31 stage I or II NK/T cell lymphoma, nasal-type patients received by CCRT, followed by adjuvant VIPD chemotherapy. Information on patient demographics, disease stage, clinical symptoms, tumor, and paraclinical characteristics were collected. The primary endpoints of this study were OS and response rates. After CCRT, 26 out of 31 (83.9%) patients had stable disease or response. Overall response rate (ORR) was observed in 80.6% of patients with a complete response rate of 67.7%. Low-risk PINK patients had a higher response rate than the intermediate- risk group (p=0.038). Mean disease-free survival was 44.3±4.5 months (95% CI, 35.4-53.1 months). Mean overall survival was 46.8±4.5 months (95% CI, 37.99-55.8 months). The intermediate-risk PINK patients had a significantly lower OS rate than low-risk patients. Concurrent chemoradiotherapy followed by adjuvant VIPD chemotherapy showed a high response rate and survival benefit in stages I-II, nasal type, and extranodal natural killer (NK)/T-cell lymphoma Vietnamese patients.
结外自然杀伤(NK)/T细胞淋巴瘤,鼻型是一种罕见、侵袭性强且预后不良的亚型。同步放化疗后序贯化疗显示出相对较高的缓解率,且治疗所致毒性可接受。本研究试图报告在越南接受CCRT序贯辅助VIPD化疗的Ⅰ-Ⅱ期鼻型结外NK/T细胞淋巴瘤患者的临床病理特征、生存结果及缓解率。本研究纳入了31例接受CCRT序贯辅助VIPD化疗的Ⅰ期或Ⅱ期NK/T细胞淋巴瘤鼻型患者。收集了患者人口统计学、疾病分期、临床症状、肿瘤及副临床特征等信息。本研究的主要终点为总生存期(OS)和缓解率。CCRT后,31例患者中有26例(83.9%)病情稳定或缓解。80.6%的患者观察到总体缓解率(ORR),完全缓解率为67.7%。低风险PINK患者的缓解率高于中风险组(p=0.038)。平均无病生存期为44.3±4.5个月(95%CI,35.4-53.1个月)。平均总生存期为46.8±4.5个月(95%CI,37.99-55.8个月)。中风险PINK患者的OS率显著低于低风险患者。同步放化疗后序贯辅助VIPD化疗在Ⅰ-Ⅱ期鼻型结外自然杀伤(NK)/T细胞淋巴瘤越南患者中显示出高缓解率和生存获益。